Multivariate Analysis for ASD Treatment Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for autism spectrum disorder (ASD) lack objective assessment and often result in delayed diagnoses, highlighting the need for improved screening and treatment approaches, particularly in understanding the metabolic and behavioral impacts of folate-dependent one-carbon metabolism and transsulfuration pathways.
Innovation Solution
A method and system utilizing multivariate statistical analysis to predict the effectiveness of treatments for ASD by developing models that classify and predict changes in metabolic profiles and adaptive behavior scores based on data from typically developing and ASD individuals, incorporating treatments like methylcobalamin, tetrahydrobiopterin, and folinic acid, and using regression analysis to quantify treatment effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical evaluation methods are used for ASD diagnosis, then comprehensive behavioral assessment is achieved, but diagnostic objectivity and precision are insufficient
Solution Approach 1:
The patent replaces subjective clinical evaluation with objective metabolic measurement systems. Mass spectrometry and other analytical instruments detect metabolic biomarkers (amino acids, acylcarnitines, glycerolipids) to provide quantifiable diagnostic data, substituting the mechanical/subjective assessment process with instrumental measurement that eliminates human bias and improves diagnostic precision.
Solution Approach 2:
The patent introduces metabolic biomarkers as intermediary indicators between behavioral observations and ASD diagnosis. These metabolic markers serve as objective mediators that reflect underlying biological mechanisms, allowing clinicians to assess ASD risk and treatment response through measurable metabolic changes rather than direct behavioral evaluation alone.
2Loss of time
If early behavioral intervention is implemented, then improved developmental outcomes are achieved, but delayed diagnosis prevents timely intervention
Solution Approach 1:
The patent enables preliminary detection of ASD risk through metabolic profiling before definitive behavioral diagnosis is established. By identifying characteristic metabolic patterns in young children (including infants), the system allows early intervention to begin while diagnostic confirmation is still being pursued, effectively performing the intervention action before the traditional diagnostic timeline would permit.
Solution Approach 2:
The patent substitutes traditional behavioral observation-based diagnosis with metabolic measurement systems that can detect ASD-related biochemical changes at very young ages. This replacement enables diagnosis at 12-24 months rather than waiting for 3-4 years, providing the time advantage needed for early intervention while maintaining diagnostic accuracy through objective biomarker detection.
3Measurement precision
If treatment effectiveness is assessed through behavioral observation alone, then comprehensive behavioral change is captured, but objective measurement of treatment impact on underlying biology is lacking
Solution Approach 1:
The patent uses metabolic biomarkers as intermediary measures to quantify treatment effects on underlying biological mechanisms. These metabolic markers provide objective mediation between treatment administration and behavioral outcome assessment, allowing clinicians to measure biochemical response to treatment (such as folate-dependent one-carbon metabolism pathway correction) independently of behavioral changes.
Solution Approach 2:
The patent segments the treatment assessment into distinct components: metabolic response measurement and behavioral outcome measurement. This segmentation allows independent evaluation of treatment effects at different levels (biological vs. behavioral), providing more granular and objective data about what aspects of treatment are working and what adjustments may be needed.
4Reliability
If metabolic pathways are corrected through treatment, then underlying biological processes are improved, but connection to behavioral symptom amelioration is not established
Solution Approach 1:
The patent implements feedback loops that connect metabolic measurement with behavioral assessment. By repeatedly measuring both metabolic biomarkers and behavioral outcomes over time, the system establishes feedback relationships that show how metabolic corrections translate to behavioral improvements. This feedback mechanism allows clinicians to adjust treatment based on the observed connection between biochemical changes and symptom amelioration.
Solution Approach 2:
The patent merges metabolic profiling with behavioral assessment into an integrated treatment monitoring system. Rather than treating these as separate evaluation streams, the system combines metabolic data (from mass spectrometry or other analytical methods) with behavioral observations to provide a unified view of treatment effectiveness, establishing the connection between biological mechanism correction and symptom improvement.
Data Source
AI summary
Fisher discriminant analysis is performed on data sets of typically developing (TD) individuals and data sets of autism spectrum disorder (ASD) individuals to produce a model that classifies TD individuals from ASD individuals. The ASD data sets include pre-treatment folate-dependent one-carbon metabolism (FOCM) and transsulfuration (TS) pathway metabolic profile data and post-treatment folate-dependent one-carbon metabolism (FOCM) and transsulfuration (TS) pathway metabolic profile data for patients receiving one or more ASD treatments. Changes in adaptive behavior are predicted by utilizing regression of changes in adaptive behavior and changes in biochemical measurements observed in the data sets. Thus, the system can be used to predict the effectiveness of a given course of treatment for an ASD patient based on measured metabolite data of that patient, or to predict the overall effectiveness of a clinical trial based on metabolite data for the trial participants.